Molecular cancer screening: in search of evidence

Cancer screening with germline genetic sequencing and liquid biopsy could facilitate early cancer detection. But testing if these technologies reduce the burden of cancer mortality will require rethinking how clinical trials are run.

Automated summary

Cancer screening through germline genetic sequencing and liquid biopsy can help with early cancer detection, but evaluating their impact on reducing cancer mortality will require rethinking the way clinical trials are conducted.